FDA Advisory Committee

Adelphi, MD – FDA Advisory Committee on Endocrinologic and Metabolic Drugs advisory committee meeting to review the use of sibutramine in the treatment of obesity.  Theodore Kyle, RPh and chair of the The Obesity Society (TOS) Advocacy Task Force, presented a statement on behalf of TOS urging the panel to balance the need for effective treatments with the need to protect patients who are poor candidates for treatment with sibutramine.

Please visit http://www.obesity.org/about/advocacy.asp for more information.